argenx SE (NASDAQ:ARGX) Receives $658.39 Consensus PT from Brokerages

Shares of argenx SE (NASDAQ:ARGX) have received a consensus recommendation of “Moderate Buy” from the twenty-two analysts that are presently covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell rating, two have assigned a hold rating, eighteen have given a buy rating and one has assigned a strong buy rating to the company. The average 1-year target price among brokers that have issued ratings on the stock in the last year is $658.39.

ARGX has been the topic of several analyst reports. HC Wainwright reaffirmed a “buy” rating and issued a $717.00 target price (up from $670.00) on shares of argenx in a research note on Tuesday, January 14th. Scotiabank raised shares of argenx from a “sector perform” rating to a “sector outperform” rating and lifted their target price for the stock from $439.00 to $715.00 in a research note on Tuesday, November 5th. JMP Securities boosted their price objective on shares of argenx from $606.00 to $696.00 and gave the company a “market outperform” rating in a research report on Tuesday, January 14th. Piper Sandler boosted their price objective on shares of argenx from $620.00 to $725.00 and gave the company an “overweight” rating in a research report on Tuesday, January 7th. Finally, Deutsche Bank Aktiengesellschaft downgraded shares of argenx from a “hold” rating to a “sell” rating in a research report on Friday, January 17th.

Hedge Funds Weigh In On argenx

A number of hedge funds have recently bought and sold shares of the company. FMR LLC boosted its stake in argenx by 35.9% in the 3rd quarter. FMR LLC now owns 4,793,472 shares of the company’s stock worth $2,598,445,000 after purchasing an additional 1,265,486 shares in the last quarter. Janus Henderson Group PLC boosted its stake in argenx by 0.4% in the 3rd quarter. Janus Henderson Group PLC now owns 2,479,207 shares of the company’s stock worth $1,343,797,000 after purchasing an additional 10,975 shares in the last quarter. Clearbridge Investments LLC raised its position in argenx by 3.6% in the 2nd quarter. Clearbridge Investments LLC now owns 617,466 shares of the company’s stock worth $265,535,000 after buying an additional 21,189 shares during the last quarter. Wellington Management Group LLP raised its position in argenx by 13.0% in the 3rd quarter. Wellington Management Group LLP now owns 482,346 shares of the company’s stock worth $261,470,000 after buying an additional 55,617 shares during the last quarter. Finally, Sei Investments Co. raised its position in argenx by 15.2% in the 2nd quarter. Sei Investments Co. now owns 381,544 shares of the company’s stock worth $164,079,000 after buying an additional 50,477 shares during the last quarter. Institutional investors own 60.32% of the company’s stock.

argenx Stock Up 1.9 %

Shares of NASDAQ ARGX opened at $652.19 on Friday. argenx has a 52 week low of $349.86 and a 52 week high of $678.21. The firm’s fifty day moving average is $624.24 and its 200 day moving average is $561.49. The company has a market cap of $39.37 billion, a price-to-earnings ratio of -741.13 and a beta of 0.59.

argenx (NASDAQ:ARGX) last issued its earnings results on Thursday, October 31st. The company reported $1.39 EPS for the quarter, topping the consensus estimate of $0.10 by $1.29. argenx had a negative net margin of 2.11% and a negative return on equity of 1.45%. The company had revenue of $588.88 million for the quarter, compared to the consensus estimate of $543.29 million. During the same period in the previous year, the firm earned ($1.25) earnings per share. Equities research analysts anticipate that argenx will post 2.78 earnings per share for the current year.

About argenx

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.